Trials / Completed
CompletedNCT03017313
To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients
A Prospective Post Marketing Non Interventional Study to Evaluate the Criteria on Which Renewal of LHRH Analogue Treatment is Made in Patients With Prostate Cancer Locally Advanced or Metastatic.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 510 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study, is to determine the percentage of patients for whom the initial LHRH prescription has been renewed
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LHRH analogues | 3-or 6-month formulations |
Timeline
- Start date
- 2017-07-13
- Primary completion
- 2021-06-14
- Completion
- 2021-06-14
- First posted
- 2017-01-11
- Last updated
- 2021-06-24
Locations
27 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT03017313. Inclusion in this directory is not an endorsement.